Clinical Trial Update: A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety, pharmacokinetics, and pharmacodynamics study of ABX464 in HIV-1 seronegative and seropositive adults completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ABX464 (ABX464)

Snippet

Sponsor: Abivax S.A. | Conditions: HIV Infections, Health Volunteers | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-03-31